BamSEC and AlphaSense Join Forces
Learn More

Outlook Therapeutics Inc.

NASDAQ: OTLK    
Share price (8/15/25): $2.34    
Market cap (8/15/25): $104 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.2
from 10-Q 79 pages Master Services Agreement ​ ​ ​ ​ (1)alloga (Nederland) B.V
12/34/56
EX-10.1
from 8-K 14 pages Executive Employment Agreement
12/34/56
EX-10.1
from 8-K 3 pages April 10, 2025 ​ Lawrence A. Kenyon via Email/Docusign ​ Dear Mr. Kenyon, ​ in Recognition of Your Contributions to Date and Our Important Future Objectives, Outlook Therapeutics, Inc. (The “Company”) Is Offering You the Retention Bonus Opportunity Described Below
12/34/56
EX-10.2
from 8-K 10 pages Convertible Promissory Note
12/34/56
EX-10.1
from 8-K 19 pages Securities Purchase Agreement
12/34/56
EX-10.2
from 8-K 17 pages January 16, 2025 To: Holder of Warrants to Purchase Common Stock Re: Inducement Offer to Exercise Warrants to Purchase Common Stock Dear Holder
12/34/56
EX-10.1
from 8-K 15 pages January 16, 2025 To: Holder of Warrants to Purchase Common Stock Re: Inducement Offer to Exercise Warrants to Purchase Common Stock Dear Holder
12/34/56
EX-10.11
from 10-K 5 pages ​ Outlook Therapeutics, Inc. Non-Employee Director Compensation Policy as Amended and Restated Effective October 1, 2024
12/34/56
EX-10.2
from 10-Q 16 pages Outlook Therapeutics, Inc. 2024 Equity Incentive Plan ​ Stock Option Grant Notice
12/34/56
EX-10.1
from 10-Q 23 pages Outlook Therapeutics, Inc. 2024 Equity Incentive Plan
12/34/56
EX-10.1
from 8-K 3 pages 1. the Defined Term “Agreement” in the Sales Agreement Is Amended to Mean the Sales Agreement as Amended by This Amendment. 2. the Second Paragraph of Section 1 of the Sales Agreement Is Hereby Amended and Restated in Its Entirety as Follows
12/34/56
EX-10.6
from 8-K 5 pages Third Amendment to Convertible Promissory Note
12/34/56
EX-10.5
from 8-K 24 pages Registration Rights Agreement
12/34/56
EX-10.4
from 8-K 44 pages Securities Purchase Agreement
12/34/56
EX-10.3
from 8-K 24 pages Registration Rights Agreement
12/34/56
EX-10.2
from 8-K 9 pages Outlook Therapeutics, Inc. Support Agreement
12/34/56
EX-10.1
from 8-K 46 pages Securities Purchase Agreement
12/34/56
EX-10.30
from 10-K 4 pages Amendment to Convertible Promissory Note
12/34/56
EX-10.26
from 10-K 5 pages Outlook Therapeutics, Inc. ​ Non-Employee Director Compensation Policy ​ as Amended and Restated Effective October 1, 2023
12/34/56
EX-10.1
from 8-K 51 pages Outlook Therapeutics, Inc. Up to $100,000,000 of Common Stock (Par Value $0.01 Per Share) At-The-Market Sales Agreement
12/34/56